Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients.

OBJECTIVE Platelet-activating factor (PAF) is a phospholipid with multiple actions that is involved in inflammatory diseases as well as in atherogenesis. It is inactivated by a plasma enzyme, PAF-acetylhydrolase (PAF-AH). Deficiency of this enzyme in plasma is caused by a missense mutation in the gene (G994T). The aim of this study was to investigate association of this mutation with premature coronary artery disease (CAD). METHODS One hundred and fifteen unrelated Turkish patients with a diagnosis of premature CAD and 128 unrelated healthy subjects were enrolled in this study. Genotyping was performed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). RESULTS The prevalence of the G994T mutation in the patients was 2.60 % (heterozygote), and 0 % in the controls. There was no significant difference in allele frequency and genotype distribution among the study groups. CONCLUSION The G9943T mutation in the plasma PAF acetylhydrolase gene is not associated with premature CAD in Turkish subjects.

[1]  J. Sugatani,et al.  Association of a G994 →T Missense Mutation in the Plasma Platelet-Activating Factor Acetylhydrolase Gene With Risk of Abdominal Aortic Aneurysm in Japanese , 2002, Annals of surgery.

[2]  Yoshiji Yamada,et al.  Association of a G994→ T (Val279→ Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy , 2001, Journal of Human Genetics.

[3]  Ç. Altay,et al.  Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. , 2001, Thrombosis research.

[4]  L. Tjoelker,et al.  Platelet-activating factor acetylhydrolases in health and disease. , 2000, Biochimica et biophysica acta.

[5]  J. Sugatani,et al.  Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. , 2000, Journal of vascular surgery.

[6]  M. Gelb,et al.  Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. , 1999, Biochemistry.

[7]  T. Fukuda,et al.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. , 1999, The Journal of clinical investigation.

[8]  M. Yokota,et al.  Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. , 1998, Circulation.

[9]  T. Imaizumi,et al.  A Mutation in Plasma Platelet-activating Factor Acetylhydrolase (Val279Phe) Is a Genetic Risk Factor for Cerebral Hemorrhage but not for Hypertension , 1998, Thrombosis and Haemostasis.

[10]  M. Yokota,et al.  Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. , 1998, Metabolism: clinical and experimental.

[11]  T. Imaizumi,et al.  A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke. , 1997, Stroke.

[12]  G. Zimmerman,et al.  Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. , 1996, The Journal of clinical investigation.

[13]  J. Sugatani,et al.  Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. , 1988, The Journal of clinical investigation.

[14]  F. Snyder,et al.  A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). , 1981, The Journal of biological chemistry.

[15]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[16]  H. Arai.  Platelet-activating factor acetylhydrolase. , 2002, Prostaglandins & other lipid mediators.

[17]  市原 佐保子.  Association of a G994→T Missense Mutation in the Plasma Platelet-Activating Factor Acetylhydrolase Gene With Genetic Susceptibility to Nonfamilial Dilated Cardiomyopathy in Japanese , 2001 .

[18]  N. Yoshikawa,et al.  Platelet-activating factor acetylhydrolase gene mutation in Japanese nephrotic children. , 1998, Kidney international.

[19]  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.

[20]  J. Polonsky,et al.  Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. , 1979 .